Cyclo Therapeutics Inc (CYTH)

[Cloner2]

https://www.ncbi.nlm.nih.gov/pubmed/26055150

From this paper.
Hearing Loss and Otopathology Following Systemic and Intracerebroventricular Delivery of 2-Hydroxypropyl-Beta-Cyclodextrin.

However, recent evidence shows that 2-hydroxypropyl-ß-cyclodextrin (HPßCD) causes severe hearing loss in mice, selectively killing outer hair cells (OHC) within 1 week of subcutaneous drug treatment. In the current study, the impact of HPßCD on auditory physiology and pathology was explored further as a function of time and route of administration. When administered subcutaneously or directly into cerebrospinal fluid, single injections of HPßCD caused up to 60 dB threshold shifts and widespread OHC loss in a dose-dependent manner.


Basically it depends on dose and delivery method but they are all ototoxic. This is likely the reason why the clinical trial is only dosing at 1.5 and 2.5g per kg. I am not sure what dose you start seeing ototoxic effect.


This is an interesting paper on the variability of ototoxic effects.

Efficacy and ototoxicity of different cyclodextrins in
Niemann–Pick C disease